Leaflet: information for the user
Nephrotect solution for infusion
Amino acid solution
Read the entire leaflet carefully before starting to use this medicine, as it contains important information for you.
Contents of the leaflet:
Nephrotect is a solution that provides amino acids as part of parenteral nutrition in patients with renal failure when other types of nutrition are not convenient. The solution can be used in patients with acute or chronic renal failure, including patients undergoing dialysis treatment.
You should not be given Nephrotect:
Warnings and precautions
Consult your doctor before you are given Nephrotect:
Normally, a blood or urine test will allow these levels to be verified.
Children
Nephrotect is not recommended for use in children.
Using Nephrotect with other medicines
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicine.
Pregnancy and breastfeeding
There is no sufficient experience with the use of Nephrotect during pregnancy and breastfeeding. Your doctor will assess the need to use this medicine.
If you are pregnant or breastfeeding, think you might be pregnant, or plan to become pregnant, consult your doctor before using this medicine. Your doctor will decide whether you should be given Nephrotect.
Driving and using machines
Not applicable, as the product is administered in a hospital.
Your doctor will decide on the dose to be administered to you individually, based on your body weight and function.
A healthcare professional will administer Nephrotect to you.
If you are given too much Nephrotect
It is unlikely that you will receive too much Nephrotect, as the product is administered by healthcare professionals.
The basic symptoms of an overdose or too rapid infusion of the solution may include:
If any of these symptoms appear, or if you think you have received too much Nephrotect, you should inform your doctor immediately, who will stop the infusion and take the necessary measures.
If you have any other questions about the use of this medicine, ask your doctor or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Reporting side effects
If you experience any side effects, consult your doctor, pharmacist, or nurse, even if they are side effects not listed in this leaflet. You can also report them directly through the Spanish Medicines and Healthcare Products Agency (AEMPS) website: http://www.aemps.gob.es/. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Composition of Nephrotect
The active substances are:
1 liter contains:
L-isoleucine | 5.80 g |
L-leucine | 12.80 g |
L-lysine acetate | 16.9 g |
= 12 g L-lysine | |
L-methionine | 2.00 g |
L-phenylalanine | 3.50 g |
L-threonine | 8.20 g |
L-tryptophan | 3.00 g |
L-valine | 8.70 g |
Arginine | 8.20 g |
L-histidine | 9.80 g |
L-alanine | 6.20 g |
Acetylcysteine | 0.54 g |
= 0.40 g L-cysteine glycine | 5.31 g |
L-proline | 3.00 g |
L-serine | 7.60 g |
L-tyrosine | 0.60 g |
N-glycyl-L-tyrosine | 3.16 g |
= 0.994 g glycine
= 2.40 g tyrosine
The other components are: acetic acid, L-malic acid, and water for injectable preparations.
Total amino acids 100 g/l
Total nitrogen 16.3 g/l
Total energy content 400 Kcal/l
pH 5.5-6.5
Acidity titration approx. 60 mmol NaOH/l
Theoretical osmolality 960 mosm/l
Appearance of the product and contents of the pack
Clear, colorless to slightly yellowish solution presented in 250 ml and 500 ml glass vials with a rubber stopper and an aluminum cap.
Size of the packs:
1 × 250 ml, 10 × 250 ml
1 × 500 ml, 10 × 500 ml
Not all pack sizes may be marketed.
Marketing authorization holder and manufacturer
Marketing authorization holder
Fresenius Kabi Deutschland GmbH
61346 Bad Homburg Germany
Manufacturer
Fresenius Kabi Austria GMBH, 8055 Graz Austria
Local representative
Fresenius Kabi España, S.A.U
Marina, 16-18
08005 Barcelona
Date of last revision of this leaflet: January 2015
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Healthcare Products (AEMPS) http://www.aemps.gob.es/
-----------------------------------------------------------------------------------------------------------------------------
This information is intended only for healthcare professionals: Contraindications
Special warnings and precautions for use
Be particularly careful with patients with hyponatremia or elevated serum osmolality.
During treatment, it is necessary to monitor fluid balance, serum electrolyte levels, acid-base balance, serum urea, and blood ammonia levels. Laboratory monitoring should also include blood glucose, serum protein, creatinine, and liver function tests.
So far, there is no clinical experience with the use of Nephrotect in children.
Posology and method of administration
For administration as a continuous intravenous infusion.
Your doctor will adjust the dose to be administered to you based on your needs.
Unless otherwise indicated, in patients with acute and chronic renal insufficiency
- patients not receiving dialysis:
0.6 - 0.8 g AAs / kg body weight / day
= 6 - 8 ml / kg body weight / day
- patients receiving dialysis
0.8 - 1.2 g AAs / kg body weight / day
= 8 - 12 ml / kg body weight / day
- for intradialytic nutrition in patients treated with long-term hemodialysis
0.5 - 0.8 g AAs / kg body weight / dialysis
= 5 - 8 ml / kg body weight / dialysis
Recommended maximum daily dose:
0.8 - 1.2 g AAs / kg body weight
= 8 - 12 ml / kg body weight, or 560 - 840 ml in a 70 kg patient
Recommended maximum infusion rates:
Parenteral nutrition:
0.1 g AAs / kg body weight / hour
Intradialytic nutrition:
0.2 g AAs / kg body weight / hour
Generally, amino acids should be administered in combination with infusion solutions, providing the patient's energy requirements during parenteral nutrition.
Nephrotect can be used for total parenteral nutrition if administered in combination with energy carriers, electrolytes, vitamins, and trace elements.
For central or peripheral venous infusion, it can be mixed with other nutrients if appropriate.
Nephrotect can be administered using separate infusion lines along with other nutritional substrates (multi-bottle / bag system), or it can be mixed in a container with other solutions to produce a total nutrient solution containing all components.
If Nephrotect is used for intradialytic nutrition, it can be injected directly into the venous drip chamber of the dialysis apparatus.
Amino acid solutions, including Nephrotect, are generally administered in combination with carbohydrates and lipids to ensure the anabolic use of amino acids. An exception is the use of amino acid supplements in intradialytic nutrition, during which a dialysate containing glucose can be used.
The duration of treatment depends on the patient's clinical condition.
If serum creatinine decreases below 300 umol / l, a conventional amino acid solution can be used.
So far, there is no clinical experience with the use of Nephrotect in children.
Compatibility
Only those medicines necessary for parenteral nutrition, such as energy carriers, electrolytes, trace elements, and vitamins, for which compatibility with Nephrotect has been studied, can be mixed with it.
The mixture must be prepared correctly.
Stability
Shelf life of the medicine in the packaged form for sale:
24 months. Store the container in its outer packaging.
Do not store above 25°C.
Shelf life after first opening of the container
The solution should be used immediately.
Any unused solution should be discarded after infusion.
Shelf life after addition of other nutritional elements
Nephrotect can be mixed with other solutions for nutrition, such as lipid emulsions, carbohydrates, electrolyte solutions, trace elements, and vitamins. Compatibility data are available upon request.
From a microbiological point of view, the product should be used immediately after the additions have been made. If it is not used immediately, the user is responsible for the storage conditions and the duration of the mixture until use. Normally, the mixture should not be stored for more than 24 hours at 2-8°C, unless the mixture has been prepared under controlled and validated aseptic conditions. If storage cannot be avoided and provided that the mixture has been prepared under controlled and validated aseptic conditions, it can be stored for a period longer than 2-8°C before use, ensuring that compatibility has been demonstrated. After removal from storage at 2-8°C, it must be infused within 24 hours.
Any unused mixture should be discarded after infusion.
Handling and disposal
Nephrotect should be used with a sterile transfer line immediately after opening. Any unused portion of the solution should be discarded.
Nephrotect is generally administered through a central venous access (preferably continuously over 24 hours).
When used for intradialytic nutrition, Nephrotect can be infused into the venous drip chamber of the dialysis apparatus, and it is not necessary to place a venous line.
The manufacturer has available, upon request, data on the chemical and physical stability of various mixtures.
Additions should be made aseptically.
Use only clear solutions and intact containers.
Do not use multiple doses from one vial.